These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29792969)

  • 1. Impact of extended-spectrum β-lactamases and carbapenem-resistant Gram-negative infections on sepsis mortality at the emergency department: a cohort study.
    Sabino S; Monroy H; Jara C; Lopez O; Ramos F; Falci DR; Rigatto MH
    J Hosp Infect; 2019 Feb; 101(2):190-191. PubMed ID: 29792969
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease.
    Ferstl PG; Filmann N; Brandt C; Zeuzem S; Hogardt M; Kempf VAJ; Müller M; Waidmann O; Reinheimer C
    Liver Int; 2017 Oct; 37(10):1488-1496. PubMed ID: 28374901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing Gram-negative bacteria isolated from ocular infections.
    Rameshkumar G; Ramakrishnan R; Shivkumar C; Meenakshi R; Anitha V; Venugopal Reddy YC; Maneksha V
    Indian J Ophthalmol; 2016 Apr; 64(4):303-11. PubMed ID: 27221683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended spectrum beta-lactamases among gram-negative bacteria from an Egyptian pediatric hospital: a two-year experience.
    Zaki Mel S
    J Infect Dev Ctries; 2007 Dec; 1(3):269-74. PubMed ID: 19734604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms.
    Kadri SS; Strich JR; Swihart BJ; Hohmann S; Dekker JP; Palmore T; Bonne S; Freeman B; Raybould J; Shah NG; Patel D; Husson J; Jacobs MD; Duong L; Follmann D; Hooper DC; Timpone J; Danner RL
    Am J Infect Control; 2019 Sep; 47(9):1040-1047. PubMed ID: 30824387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting acquisition of carbapenem-resistant Gram-negative pathogens in intensive care units.
    Dantas LF; Dalmas B; Andrade RM; Hamacher S; Bozza FA
    J Hosp Infect; 2019 Oct; 103(2):121-127. PubMed ID: 31039381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-spectrum β-lactamase-producing bacteria caused less than 5% of urinary tract infections in a paediatric emergency centre.
    Jacmel L; Timsit S; Ferroni A; Auregan C; Angoulvant F; Chéron G
    Acta Paediatr; 2017 Jan; 106(1):142-147. PubMed ID: 27542840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faecal carriage of ESBL-producing Enterobacteriaceae and carbapenem-resistant Gram-negative bacilli in community settings.
    Villar HE; Baserni MN; Jugo MB
    J Infect Dev Ctries; 2013 Aug; 7(8):630-4. PubMed ID: 23949299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired metallo-beta-lactamases: an increasing clinical threat.
    Rossolini GM
    Clin Infect Dis; 2005 Dec; 41(11):1557-8. PubMed ID: 16267726
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical implications of inducible beta-lactamase activity in Gram-negative bacteremia in children.
    Boyle RJ; Curtis N; Kelly N; Garland SM; Carapetis JR
    Pediatr Infect Dis J; 2002 Oct; 21(10):935-40. PubMed ID: 12394816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections.
    Tabak YP; Sung AH; Ye G; Vankeepuram L; Gupta V; McCann E
    J Hosp Infect; 2019 May; 102(1):37-44. PubMed ID: 30503367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
    Boyle DP; Zembower TR
    Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing incidence of multidrug-resistant Gram-negative septicaemia during induction therapy of acute myeloid leukaemia.
    Murali NA; Ganesan P; Vijayakumar V; Kannan K; Radhakrishnan V; Ganesan TS; Sagar TG
    J Hosp Infect; 2016 Jul; 93(3):314-5. PubMed ID: 27206967
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of extended-spectrum-beta-lactamase and metallo-beta-lactamase producing multi drug resistance gram- negative bacteria from urinary isolates.
    Jena J; Debata NK; Subudhi E
    Indian J Med Microbiol; 2013; 31(4):420-1. PubMed ID: 24064661
    [No Abstract]   [Full Text] [Related]  

  • 17. Carbapenem-resistant gram-negative bacilli in Tripoli, Libya.
    Kraiem AG; Zorgani A; Elahmer O; El Salabi AA; Ghenghesh KS
    Am J Infect Control; 2016 Oct; 44(10):1192-1194. PubMed ID: 27473769
    [No Abstract]   [Full Text] [Related]  

  • 18. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of MRSA and Gram-negative bacteria with ESBLs and carbapenemases in patients from Northern Africa at a German hospital.
    Leistner R; Denkel LA; Gastmeier P; Werner G; Layer F; Pfeifer Y
    J Antimicrob Chemother; 2015 Nov; 70(11):3161-4. PubMed ID: 26216582
    [No Abstract]   [Full Text] [Related]  

  • 20. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
    Bradford PA
    Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.